Trial Profile

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mogamulizumab (Primary) ; Vorinostat
Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
Focus Registrational; Therapeutic Use
Acronyms MAVORIC
Sponsors Kyowa Kirin; Kyowa Kirin International; Kyowa Kirin Pharmaceutical Development

10 Jun 2026 According to a Kyowa Kirin media release, data from this study will be presented at the World Congress of Cutaneous Lymphomas (WCCL) in Montreal, Canada.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results of retrospective, post Hoc analysis of Health-Related Quality of Life in Cutaneous T-Cell Lymphoma, presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com